EC Number |
Inhibitors |
Structure |
---|
3.4.21.95 | Acetylsalicylic acid |
aspirin, reduces markedly platelet aggregating effect induced by VLCII, less effective compared to clopidogrel |
|
3.4.21.95 | ADP |
reduces slightly platelet aggregating effect induced by VLCII |
|
3.4.21.95 | clopidogrel |
P2Y12 adenosine diphosphate (ADP) receptor inhibitor, reduces markedly platelet aggregating effect induced by VLCII |
|
3.4.21.95 | D-Phe-Pro-Arg-chloromethylketone |
- |
|
3.4.21.95 | diisopropyl fluorophosphate |
- |
|
3.4.21.95 | diisopropylfluorophosphate |
- |
|
3.4.21.95 | heparin |
at high concentrations, more than 100 units |
|
3.4.21.95 | more |
no inhibition of the proteolytic activity of VLCII by EDTA and 1,10-phenanthroline, poor inhibition by EGTA. VLCII activity on platelet aggregation is tested after treatment with acetylsalicylic acid (aspirin) irreversible inhibitor of cyclooxygenase-1 (COX-1) and clopidogrel (plavix) antagonist of P2Y12 receptor |
|
3.4.21.95 | pefabloc |
4-(2-aminoethyl)-benzenesulfonyl fluoride |
|
3.4.21.95 | PMSF |
82% inhibition |
|